LEXINGTON, Mass., March 19, 2014 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the company will present at two upcoming conferences: the 13th International Geneva-Springfield Symposium on Advances in Alzheimer’s Therapy and the 21st Annual BioCentury Future Leaders in the Biotech Industry investor conference.
Mark Versavel, MD, PhD, MBA, Chief Medical Officer of Alzheon, will make the presentation at the Geneva-Springfield Symposium on Advances in Alzheimer’s Therapy at 5:20 PM CET (11:20 AM ET) on Thursday, March 27, 2014, at the International Conference Centre in Geneva, Switzerland. The presentation titled “ALZ-801, a Novel Prodrug of Tramiprosate Which Improves Cognition and Function in ApoE4 Positive in Alzheimer’s Disease Patients” will provide an overview of the clinical data and subpopulation analyses in more than 2,000 Alzheimer’s patients from Phase 3 studies with the parent molecule tramiprosate, supporting and guiding the development of Alzheon’s lead clinical candidate prodrug ALZ-801.
Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon, will present at the BioCentury Future Leaders conference at 2:00 PM ET on Friday, March 28, 2014, at the Millennium Broadway Hotel in New York, NY. Dr. Tolar will provide an overview of Alzheon’s drug development approach and pipeline in Alzheimer’s disease, including the clinical program for ALZ-801 to start confirmatory pivotal Phase 2/3 study in early 2015 in Alzheimer’s disease patients positive for ε4 allele of the apolipoprotein E.
About Alzheon
Alzheon, Inc., is a clinical-stage biotechnology company focused on brain health, memory and aging, developing innovative treatments for Alzheimer’s disease and other neurodegenerative disorders. Alzheon pursues drug development programs with an established safety profile that have previously been tested in extensive efficacy studies in Alzheimer’s disease patients, and where new insights into a disease or molecule can be applied. Based on a drug development platform that yields diverse and novel compounds, the company is building a pipeline of innovative drugs to target the underlying pathogenesis of neurodegeneration in order to improve the symptoms and slow the progression of these devastating diseases. Our lead product candidate, ALZ- 801, is a first-in-class small molecule inhibitor of amyloid aggregation and neurotoxicity, and is advancing into a confirmatory pivotal Phase 2/3 study for certain patient populations with Alzheimer’s disease or at risk for the disease. Alzheon has worldleading capabilities in drug development for Alzheimer’s disease and related disorders, and we apply state-of-the-art clinical development approaches to improve the likelihood of success with product candidates in our pipeline, as well as additional therapeutic assets from in-licensing.
Media Contact:
Kathryn Morris
The Yates Network
Tel: 845‐635‐9828
kathryn@theyatesnetwork.com